ArticleVaccines2022
Reinfection with SARS-CoV-2 and Waning Humoral Immunity: A Case Report.
Article in Vaccines, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed, 3 syntheses or guidelines pooled it, 46 citations in OpenAlex.
- Does potential antibody-dependent enhancement occur during SARS-CoV-2 infection after natural infection or vaccination? A meta-analysis.BMC infectious diseases · 2022Pooled it
- SARS-CoV-2 Reinfection Is a New Challenge for the Effectiveness of Global Vaccination Campaign: A Systematic Review of Cases Reported in Literature.International journal of environmental research and public health · 2021Pooled it
- Repeated SARS-CoV-2 Positivity: Analysis of 123 Cases.Viruses · 2021Pooled it
- Article
- Disentangling SARS-CoV-2 Sustained Viremia Cases: Evolution, Persistence and Reinfection.Viruses · 2026Article
- Anti-SARS-CoV-2 IgM Antibody Levels Measured by an In-House ELISA in a Convalescent Latin Population Persist over Time and Exhibit Neutralizing Capacity to Several Variants of Concern.Diagnostics (Basel, Switzerland) · 2024Article
- An Update on SARS-CoV-2 Clinical Trial Results-What We Can Learn for the Next Pandemic.International journal of molecular sciences · 2023Review
- Previous infection with seasonal coronaviruses does not protect male Syrian hamsters from challenge with SARS-CoV-2.Nature communications · 2023Article
- Refocus on Immunogenic Characteristics of Convalescent COVID-19 Challenged by Prototype SARS-CoV-2.Vaccines · 2023Article
- Article
- Article
- Healthcare-Associated SARS-CoV-2 Reinfection after 3 Months with a Phylogenetically Distinct Omicron Variant: A Case Report.Viruses · 2022Article
- Article
- Evaluation of methylene blue based photodynamic inactivation (PDI) against intracellular B-CoV and SARS-CoV2 viruses under different light sources in vitro as a basis for new local treatment strategies in the early phase of a Covid19 infection.Photodiagnosis and photodynamic therapy · 2022Article
- Emerging COVID-19 reinfection four months after primary SARS-CoV-2 infection.Wiener medizinische Wochenschrift (1946) · 2022Article
- The mystery of COVID-19 reinfections: A global systematic review and meta-analysis.Annals of medicine and surgery (2012) · 2021Review
- A case of COVID-19 Reinfection and Systematic Review of Patterns of Reinfection.Infectious diseases in clinical practice (Baltimore, Md.) · 2021Article
- Article
- Complexities in Case Definition of SARS-CoV-2 Reinfection: Clinical Evidence and Implications in COVID-19 Surveillance and Diagnosis.Pathogens (Basel, Switzerland) · 2021Review
- Prolonged presence of replication-competent SARS-CoV-2 in mildly symptomatic individuals: A report of two cases.Journal of medical virology · 2021Article
Corrections and comments
- Update of
Authors and funding
33 authors at 7 institutions in 1 country.
Funding
Abstract
Recovery from COVID-19 is associated with production of anti-SARS-CoV-2 antibodies, but it is uncertain whether these confer immunity. We describe viral RNA shedding duration in hospitalized patients and identify patients with recurrent shedding. We sequenced viruses from two distinct episodes of symptomatic COVID-19 separated by 144 days in a single patient, to conclusively describe reinfection with a different strain harboring the spike variant D614G. This case of reinfection was one of the first cases of reinfection reported in 2020. With antibody, B cell and T cell analytics, we show correlates of adaptive immunity at reinfection, including a differential response in neutralizing antibodies to a D614G pseudovirus. Finally, we discuss implications for vaccine programs and begin to define benchmarks for protection against reinfection from SARS-CoV-2.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.